NightHawk Biosciences Inc

NHWK

$

Closing

1D

YTD

Market cap

$

52 week high

$

52 week low

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$

Analysts' Rating

HOLD

Price Target (Mean)

10

Total Analysts

1

P/E

Operating Margin

-1529.43%

Beta

Revenue Growth (Annual)

202.12%

52 week high

$

52 week low

$

Div. Yield

%

EPS Annual Growth

-5.66

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Nighthawk Biosciences, Inc. is a biopharmaceutical company. The Company specializes in the end-to-end development, manufacturing, and commercialization of medical countermeasures that combat unmet and emerging biothreats. It provides process development and biomanufacturing services to support its biotherapeutics and discovery pipeline. The Company’s monoclonal antibody ANTHIM (obiltoxaximab) is a monoclonal antibody that binds the protective antigen (PA) component of anthrax. Obiltoxaximab’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage that leads to death. The Company offers RapidVax as a flexible plug-and-play vaccine platform designed to leverage gp96-based vaccines and couples the immune-activating properties of heat shock protein gp96 and the T-cell co-stimulator OX40L with a flexible antigen expression system to promote antigen-specific T-cell activation.